Evaluation of Circulating GPC4 in Patients with End-Stage Kidney Disease.

BACKGROUND

Glypican-4 (GPC4) is a cell-surface heparan sulfate proteoglycan that can be released into circulation under various clinical conditions. Elevated levels of circulating GPC4 have recently been associated with reduced kidney function and an increased risk of all-cause mortality across different patient populations. The potential of circulating GPC4 for assessing disease status or prognosis in patients with end-stage kidney disease has not yet been explored and was addressed in the present study.

METHODS

The study included 187 patients starting chronic dialysis treatment. In addition, 108 control subjects with normal or mildly reduced kidney function, matched for sex and age, were included in the study. The median follow-up time of incident dialysis patients was 3.8 years. Blood samples were collected immediately before initiation of dialysis. Serum GPC4 levels were determined using an enzyme-linked immunosorbent assay.

RESULTS

Serum GPC4 levels were approximately 10-fold higher in incident dialysis patients compared to controls demonstrating excellent classification ability to distinguish between the two groups. Furthermore, circulating GPC4 was significantly positively correlated with creatinine and phosphate and significantly negatively correlated with estimated glomerular filtration rate, hemoglobin, erythrocytes, calcium, and cholinesterase in incident dialysis patients. There was no significant association between GPC4 levels and all-cause mortality in patients starting dialysis.

CONCLUSIONS

GPC4 levels were markedly elevated in patients initiating dialysis and were linked with several pathophysiological characteristics commonly observed in end-stage kidney disease. However, our findings did not indicate that elevated serum GPC4 levels serve as a significant predictor of all-cause mortality in this patient population.